Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production

The ErbB2 blocker trastuzumab improves survival in oncologic patients, but can cause cardiotoxicity. The late Na+ current inhibitor ranolazine has been shown to counter experimental HF, including doxorubicin cardiotoxicity (a condition characterized by derangements in redox balance), by lowering the...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Gennaro, Antonucci, Salvatore, Coppola, Carmela, D'Avino, Chiara, Piscopo, Giovanna, Fiore, Danilo, Maurea, Carlo, Russo, Michele, Rea, Domenica, Arra, Claudio, Condorelli, Gerolama, Di Lisa, Fabio, Tocchetti, Carlo G., De Lorenzo, Claudia, Maurea, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808165/
https://www.ncbi.nlm.nih.gov/pubmed/29467663
http://dx.doi.org/10.3389/fphys.2018.00038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808165/
https://www.ncbi.nlm.nih.gov/pubmed/29467663
http://dx.doi.org/10.3389/fphys.2018.00038

Ejemplares similares